ClinicalTrials.gg
RecruitingNCT07237451CARE FOR CKD HUpdated Nov 19, 2025

Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients

An observational study in CKD - Chronic Kidney Disease, Heart Failure Preserved Ejection Fraction and SGLT2 Inhibitors, sponsored by Grigore T. Popa University of Medicine and Pharmacy. Recruiting at 1 site in Romania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Grigore T. Popa University of Medicine and Pharmacy · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Renal Insufficiency, Chronic with a site in Romania — 8 open to participants now, 11 under way, 7 of them phase 3. Renal Insufficiency, Chronic · Romania.

Started
2025
with 2 others
Observational
9 of 65
3 open now
Primary completion
2027-03
later than 0 of 10 live
Registered
60th of 65
by date
Lead sponsor
4 of 65
Grigore T. Popa University of Medicine and Pharmacy

Among the 65 studies in Renal Insufficiency, Chronic with a site in Romania, this one is one of 3 that started in 2025, is one of 9 observational ones, reaches primary completion later than 0 of the 10 other live ones, and was the 60th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

8 of the 65 studies in Renal Insufficiency, Chronic with a site in Romania are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Renal Insufficiency, Chronic with a site in Romania, or all of them as a file.
02

Study summary

The main aim of this study is to holistically assess the cardiovascular and renal outcomes in HFpEF CKD patients with and without SGLT2 inhibition, with focus on the endothelial disfunction, MACE and mortality using clinical evaluation, flow mediated dilatation, carotid-femoral pulse wave velocity, intima-media thickness, echocardiographic parameters, NMR metabolomics and a series of novel biomarkers.

Read the detailed description

Chronic kidney disease (CKD) is considered to become the 5th cause of death worldwide by 2040. Aging populations, growing frequency of type 2 diabetes, hypertension, a low detection rate and therapeutic inertia in the early stages of CKD determined the increasing incidence and prevalence. CKD patients exhibit an elevated cardiovascular risk manifesting myocardial infarction and stroke, coronary artery disease, heart failure (HF), arrhythmias, and sudden cardiac death. The relationship between HF and CKD is bidirectional, with chronic HF promoting CKD development (cardio-renal syndrome type 1), and CKD promoting the development of HF (type 3). In the last decade, HF with preserved ejection fraction (HFpEF) represents the typical phenotype in patients with CKD, accounting for more than half of the cases of HF. Given the high burden of both HF and CKD, their complex interaction and challenging management, along with the prognostic implications regarding comorbidity and mortality, a comprehensive approach in the HFpEF population is mandatory, since HF diagnosis was evasive for years. The main aim of this study is to holistically assess the cardiovascular and renal outcomes in HFpEF CKD patients with and without SGLT2 inhibition, with focus on the endothelial disfunction, MACE and mortality using clinical evaluation, flow mediated dilatation, carotid-femoral pulse wave velocity, intima-media thickness, echocardiographic parameters, NMR metabolomics and a series of novel biomarkers.

The objectives of this prospective observational study are to determine:

  • the feasibility of PWV measurement and ventricular strain in HFpEF CKD patients with and without SGLT2 inhibition;
  • the cardiovascular outcomes, namely MACE, defined as time to first non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure or CV death and on all-cause mortality in HFpEF CKD patients with and without SGLT2 inhibition;
  • the renal outcomes, such as rapid progression of renal disease - defined as sustained annual decline of at least 5mL/min/1,73m2 in eGFR or a sustained drop of 25% or more in eGFR within 12 months;
  • the metabolomics profile related to uremic toxins panel determined by NMR spectroscopy and other biological markers as novel molecules with a higher potential accuracy of predicting further major cardiovascular events in HFpEF CKD patients with and without SGLT2 inhibition.
03

Conditions studied

  • CKD - Chronic Kidney Disease
  • Heart Failure Preserved Ejection Fraction
  • SGLT2 Inhibitors
  • Diabetes (DM)

Keywords

  • CKD
  • HFpEF
  • SGTL2 inhibitors
  • Biomarkers
  • PWV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with CKD stages 3 and 4 (eGFR calculated by CKD-EPI) with HFpEF

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age>18 years;
  • > 40;
  • patients with CKD stage 3-4 ( between 15-60 mL/min/1.73m2), with iSGLT2 recommendation, diabetic and non-diabetic;
  • age, sex and CKD stage 3 and 4 matched patients without iSGLT2 administration.

Exclusion criteria

Exclusion Criteria:

  • \< 15 mL/min/1.73m2 or patients undergoing dialysis;
  • presence of congenital heart disease, decompensated cirrhosis, pregnancy and active ;
  • coronary artery disease (including those with a history of acute coronary syndrome, angina pectoris, or prior coronary angiography or CT angiography demonstrating significant coronary artery lesions);
  • cardiac medical devices, namely metallic joint prostheses, cardiac stent or pacemakers;
  • active systemic infections (due to interference with biomarkers that can give false rise values).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • iSGLT2 therapy

    CKD and HFpEF with iSGLT2 therapy

    Diagnostic Test: Arterial stiffness · Diagnostic Test: Echocardiography · Other: Biomarkers determination · Other: NMR metabolomics and uremic toxins mapping

  • Control

    CKD and HFpEF without iSGLT2 therapy

    Diagnostic Test: Arterial stiffness · Diagnostic Test: Echocardiography · Other: Biomarkers determination · Other: NMR metabolomics and uremic toxins mapping

Interventions

  • Diagnostic testArterial stiffness

    Arterial stiffness assessment will be performed by applanation tonometry with the patient being recumbent, 10 minutes before the measures were done. The carotid and femoral pulse will be acquired by applanation tonometry sequentially, allowing a single operator to acquire the measurement. The transit time from the R-wave of the simultaneously acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference between these 2 transit times is divided by distances measured from the body surface to estimate the arterial path length in order to calculate carotid-femoral PWV.

  • Diagnostic testEchocardiography

    Echocardiography will be performed on each patient at baseline; the measurements will be carried out according to the recommendations of the American Society of Echocardiography. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).

  • OtherBiomarkers determination

    NT-pro BNP, Syndecan-1, VCAM-1, Endoglin, NO and ADMA will be determined by specific enzyme linked immunosorbent assay (ELISA) kits.

  • OtherNMR metabolomics and uremic toxins mapping

    The aliquoted serum preserved at -80° C will be analysed by NMR using deuterated solvents (D2O, CDCl3, CD3OD, CD3CN), standards of metabolites and uremic toxins.

06

What researchers measure

Primary outcomes

  1. MACE

    Composite CV outcome: time to first non-fatal myocardial infarction, non-fatal stroke, and hospitalization for heart failure or CV death

    Time frame: 20 months

  2. All-cause mortality

    All-cause mortality

    Time frame: 10 and 20 months

Secondary outcomes

  1. Composite renal outcome

    Rapid progression of renal disease - defined as sustained annual decline of at least 5mL/min/1,73m2 in eGFR or a sustained drop of 25% or more in eGFR within 10 months

    Time frame: 10 and 20 months

Other outcomes

  1. Changes in cardiac biomarkers

    Blood levels of NT-pro BNP, Syndecan-1, VCAM-1, Endoglin, NO and ADMA will be measured at baseline and months 10 and 20. The outcome is defined as the change from baseline.

    Time frame: Baseline, 10 and 20 months

  2. Changes in the NMR metabolomics and uremic toxins mapping

    Blood levels of NMR metabolomics and uremic toxins will be measured at baseline and months 10 and 20. The outcome is defined as the change from baseline.

    Time frame: Baseline, 10 and 20 months

07

Study locations

1 of 1 sites recruiting
  • Dr. C.I. Parhon Hospital in Iasi
    Iași, Romania
    Recruiting
    • Adrian Covic C Head of Nephrology Clinic, MD, PhD · Contactadrian.covic@umfiasi.ro · +40232211818
    • Gianina Dodi Researcher, PhD · Contactgianina.dodi@umfiasi.ro · +40232211818
    • Adrian Covic, MD, PhD · Principal investigator
    • Anca Stefan, MD · Sub investigator
    • Alexandra Covic, MD · Sub investigator
    • Gianina Dodi, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Mar 2027, 25 months after the start.

Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 25 months is below that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 19, 2025
StartActual
Jan 8, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07237451
Lead sponsor
Grigore T. Popa University of Medicine and Pharmacy
Collaborators
Dr. C.I. Parhon Hospital, Iasi, The Executive Agency for Higher Education, Research, Development and Innovation Funding
Responsible party
Adrian Covic (Professor, Grigore T. Popa University of Medicine and Pharmacy) — Principal investigator
First posted
Nov 19, 2025
Start date
Jan 8, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion